Bristol Myers Squibb (BMS; NYSE: BMY) has made a significant move in the field of oncology by purchasing ORM-6151, a potential first-in-class antibody-drug conjugate (ADC) from US-based Orum Therapeutics. The acquisition includes approval from the local regulator for ORM-6151 to enter a Phase I study for acute myeloid leukemia (AML) and high-risk myelodysplastic syndromes. BMS is investing USD 100 million upfront in the program, with the potential for up to USD 180 million in milestone payments.
ORM-6151’s Dual-Precision Approach
ORM-6151 is a novel candidate that combines the ADC strategy with targeted protein degradation, focusing on CD33-expressing cancer cells. It delivers a molecular glue payload that mediates the elimination of the GSPT1 protein, inducing cell death. This innovative dual-precision approach is anticipated to enhance the therapeutic window of the medicine, offering a more targeted and effective treatment option for patients.
BMS’s Competitive Edge in ADCs
By acquiring ORM-6151, BMS is positioning itself at the forefront of next-generation ADC development, distinguishing itself from competitors who are primarily focused on conventional ADCs. This strategic purchase aligns with BMS’s commitment to innovation in cancer treatment and its ambition to lead the market in advanced therapeutics. According to the public data, BMS had earlier this year entered into an agreement with Tubulis for its ADC payloads, further demonstrating the company’s active pursuit of cutting-edge oncology solutions.- Flcube.com
